NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD.
<h4>Aims</h4>To develop, validate and compare a non-invasive fibrosis scoring system for non-alcoholic fatty liver disease (NAFLD) derived from routinely obtained clinical and biochemical parameters.<h4>Methods</h4>267 consecutive patients with biopsy proven fatty liver or no...
Guardado en:
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0c5f33f797934c369e505e373d9cada5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:0c5f33f797934c369e505e373d9cada5 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:0c5f33f797934c369e505e373d9cada52021-11-18T07:52:04ZNIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD.1932-620310.1371/journal.pone.0058360https://doaj.org/article/0c5f33f797934c369e505e373d9cada52013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23555578/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Aims</h4>To develop, validate and compare a non-invasive fibrosis scoring system for non-alcoholic fatty liver disease (NAFLD) derived from routinely obtained clinical and biochemical parameters.<h4>Methods</h4>267 consecutive patients with biopsy proven fatty liver or non-alcoholic steatohepatitis were randomly assigned to the estimation (2/3) or validation (1/3) group to develop a model for the prediction of advanced fibrosis. Univariate statistics were performed to compare patients with and without advanced fibrosis, and following a multivariate logistic regression analysis a new scoring system was constructed. This non-invasive Koeln-Essen-index (NIKEI) was validated and compared to the FIB-4 index by calculating the area under the receiver operating characteristic curve (AUC). We evaluated a stepwise combination of both scoring systems for the precise prediction of advanced fibrosis. To set in contrast, we additionally tested the diagnostic accuracy of the AST/ALT ratio, BARD score and the NAFLD fibrosis score in our cohort.<h4>Results</h4>Age, AST, AST/ALT ratio, and total bilirubin were identified as significant predictors of advanced fibrosis and used to construct the NIKEI with an AUC of 0.968 [0.937; 0.998] compared to 0.929 [0.869; 0.989] for the FIB-4 index. The absence of advanced fibrosis could be confirmed with excellent accuracy (99-100%). The positive predictive value of the FIB-4 index was higher (100% vs. 60%), however, the false negative rate was also high (33%). With a stepwise combination of both indices 82%-84% of biopsies would have been avoidable without a single misclassification. The AUROC for AST/ALT ratio, the NAFLD fibrosis score, and the BARD score were 0.81 (95% CI, 0.72-0.90), 0.96 (95% CI 0.92-0.99), and 0.67 (95% CI 0.55-0.78), respectively.<h4>Conclusion</h4>The NIKEI can reliably exclude advanced fibrosis in subjects with NAFLD. In combination with the FIB-4 index misclassification with inadequate clinical management can be avoided while the need for liver biopsies can be reduced.Münevver DemirSonja LangMartin SchlattjanUta DrebberInga WedemeyerDirk NierhoffIngrid KaulJan SowaAli CanbayUlrich TöxHans-Michael SteffenPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 3, p e58360 (2013) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Medicine R Science Q |
spellingShingle |
Medicine R Science Q Münevver Demir Sonja Lang Martin Schlattjan Uta Drebber Inga Wedemeyer Dirk Nierhoff Ingrid Kaul Jan Sowa Ali Canbay Ulrich Töx Hans-Michael Steffen NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD. |
description |
<h4>Aims</h4>To develop, validate and compare a non-invasive fibrosis scoring system for non-alcoholic fatty liver disease (NAFLD) derived from routinely obtained clinical and biochemical parameters.<h4>Methods</h4>267 consecutive patients with biopsy proven fatty liver or non-alcoholic steatohepatitis were randomly assigned to the estimation (2/3) or validation (1/3) group to develop a model for the prediction of advanced fibrosis. Univariate statistics were performed to compare patients with and without advanced fibrosis, and following a multivariate logistic regression analysis a new scoring system was constructed. This non-invasive Koeln-Essen-index (NIKEI) was validated and compared to the FIB-4 index by calculating the area under the receiver operating characteristic curve (AUC). We evaluated a stepwise combination of both scoring systems for the precise prediction of advanced fibrosis. To set in contrast, we additionally tested the diagnostic accuracy of the AST/ALT ratio, BARD score and the NAFLD fibrosis score in our cohort.<h4>Results</h4>Age, AST, AST/ALT ratio, and total bilirubin were identified as significant predictors of advanced fibrosis and used to construct the NIKEI with an AUC of 0.968 [0.937; 0.998] compared to 0.929 [0.869; 0.989] for the FIB-4 index. The absence of advanced fibrosis could be confirmed with excellent accuracy (99-100%). The positive predictive value of the FIB-4 index was higher (100% vs. 60%), however, the false negative rate was also high (33%). With a stepwise combination of both indices 82%-84% of biopsies would have been avoidable without a single misclassification. The AUROC for AST/ALT ratio, the NAFLD fibrosis score, and the BARD score were 0.81 (95% CI, 0.72-0.90), 0.96 (95% CI 0.92-0.99), and 0.67 (95% CI 0.55-0.78), respectively.<h4>Conclusion</h4>The NIKEI can reliably exclude advanced fibrosis in subjects with NAFLD. In combination with the FIB-4 index misclassification with inadequate clinical management can be avoided while the need for liver biopsies can be reduced. |
format |
article |
author |
Münevver Demir Sonja Lang Martin Schlattjan Uta Drebber Inga Wedemeyer Dirk Nierhoff Ingrid Kaul Jan Sowa Ali Canbay Ulrich Töx Hans-Michael Steffen |
author_facet |
Münevver Demir Sonja Lang Martin Schlattjan Uta Drebber Inga Wedemeyer Dirk Nierhoff Ingrid Kaul Jan Sowa Ali Canbay Ulrich Töx Hans-Michael Steffen |
author_sort |
Münevver Demir |
title |
NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD. |
title_short |
NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD. |
title_full |
NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD. |
title_fullStr |
NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD. |
title_full_unstemmed |
NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD. |
title_sort |
nikei: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with nafld. |
publisher |
Public Library of Science (PLoS) |
publishDate |
2013 |
url |
https://doaj.org/article/0c5f33f797934c369e505e373d9cada5 |
work_keys_str_mv |
AT munevverdemir nikeianewinexpensiveandnoninvasivescoringsystemtoexcludeadvancedfibrosisinpatientswithnafld AT sonjalang nikeianewinexpensiveandnoninvasivescoringsystemtoexcludeadvancedfibrosisinpatientswithnafld AT martinschlattjan nikeianewinexpensiveandnoninvasivescoringsystemtoexcludeadvancedfibrosisinpatientswithnafld AT utadrebber nikeianewinexpensiveandnoninvasivescoringsystemtoexcludeadvancedfibrosisinpatientswithnafld AT ingawedemeyer nikeianewinexpensiveandnoninvasivescoringsystemtoexcludeadvancedfibrosisinpatientswithnafld AT dirknierhoff nikeianewinexpensiveandnoninvasivescoringsystemtoexcludeadvancedfibrosisinpatientswithnafld AT ingridkaul nikeianewinexpensiveandnoninvasivescoringsystemtoexcludeadvancedfibrosisinpatientswithnafld AT jansowa nikeianewinexpensiveandnoninvasivescoringsystemtoexcludeadvancedfibrosisinpatientswithnafld AT alicanbay nikeianewinexpensiveandnoninvasivescoringsystemtoexcludeadvancedfibrosisinpatientswithnafld AT ulrichtox nikeianewinexpensiveandnoninvasivescoringsystemtoexcludeadvancedfibrosisinpatientswithnafld AT hansmichaelsteffen nikeianewinexpensiveandnoninvasivescoringsystemtoexcludeadvancedfibrosisinpatientswithnafld |
_version_ |
1718422832400039936 |